[Infliximab].
Infliximab is a chimeric monoclonal antibody, which specifically binds to tumor necrosis factor (TNF-alpha) and blocks its activity. Based on previous evidence that TNF-alpha has been involved in the pathogenesis of psoriasis, multiple controlled trials have shown that infliximab has provided a high degree of clinical benefit in the treatment of psoriasis and psoriatic arthritis allowing a major and rapid improvement in these patients. We review several clinical trials, which have firmly established both efficacy and safety of Infliximab in the treatment of moderate to severe psoriasis and psoriatic arthritis.